CVS Health Corp., US1266501006

CVS Health stock holds firm after a $93.15 open

Published on 09/01/2026 at 12:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CVS Health stock traded at $93.15 after an August 31, 2026 open, with a $119.14 billion market value and a recent quarter that brought $106.10 billion in revenue and $2.58 in EPS.

Schwarzweiß-Reportagefoto eines Apothekers beim Befüllen von Rezeptmedikamenten an der Theke
CVS Health Corp. dokumentiert Schwarzweiß-Reportage eines Apothekers bei der Rezeptabgabe, ISIN US1266501006, Illustration mit AI erstellt.

CVS Health Corp. (US1266501006) traded at $93.15 after opening on August 31, 2026, with a market value of $119.14 billion. The latest reported quarter, released on August 5, 2026, showed $106.10 billion in revenue and $2.58 in EPS, both above the market's $100.03 billion and $1.87 expectations.

Latest quarter

The same quarter delivered 7.3% year-over-year revenue growth and a net margin of 1.18%. That combination matters because CVS also kept full-year 2026 EPS guidance at $7.90 to $8.10, while sell-side analysts modeled $8.02 for the year.

The spread between those figures is narrow enough to keep the debate centered on execution rather than direction. A $93.15 opening print against a $107.17 consensus target leaves room for that debate to stay active.

Chart and consensus

The shares sit between a 52-week low of $69.51 and a 52-week high of $110.68, and the stock was up 17.25% for the year in a recent market-data snapshot. That gap shows a market that has already rewarded CVS, but still leaves it below the recent high.

Recent coverage also pointed to 22 Buy ratings and two Holds, alongside that $107.17 average target. For investors, the more important comparison is that the stock price is still below the consensus mark even after the strong second quarter.

Core businesses

Aetna, CVS Pharmacy, and MinuteClinic remain the group's most visible operating pieces. In practical terms, the latest quarter's $106.10 billion revenue base and 7.3% growth show why pharmacy volume and health-benefits margins remain the numbers to watch.

Historically, the business has also leaned on scale: in the second quarter of 2026, Caremark and the health-benefits side both fed into the earnings beat. That mix gives the market a concrete reason to focus on operating discipline rather than a single segment.

What the market pays for

CVS Health's current setup is a simple one: a large revenue base, a margin that stayed at 1.18%, and guidance that still brackets the market's estimate at $8.02 in EPS. The stock's $119.14 billion market value reflects that combination more than any single catalyst.

The valuation conversation also stays tethered to scale. A business that just posted $106.10 billion in quarterly revenue does not need a dramatic narrative to move the share price; it needs the next quarter to keep the same beat-and-raise pattern intact.

Aetna and pharmacy mix

Aetna, CVS Pharmacy, and MinuteClinic are the representative parts of the company that matter most for day-to-day execution. The latest quarter's 7.3% revenue growth and $2.58 EPS suggest that the mix between insurance, pharmacy, and consumer access is still producing visible results.

Shares and valuation

CVS Health stock opened at $93.15 on August 31, 2026, against a market cap of $119.14 billion and a 52-week range of $69.51 to $110.68.

Company facts

Company: CVS Health Corp.
ISIN: US1266501006
Ticker: CVS
Exchange: NYSE
Price (as of August 31, 2026, 10:59 p.m. ET): $93.15 USD
Market cap: $119.14 billion (as of August 31, 2026)
Sector / Industry: Health Care / Healthcare Providers & Services
Index membership: S&P 500

Disclaimer...

en | US1266501006 | CVS HEALTH CORP. | boerse | 70035382 | bgmi